AstraZeneca’s Evusheld, the only COVID-19 preexposure prophylaxis treatment with emergency use authorization, isn’t expected to be as effective against new variants, the FDA said in October. The drug is usually used for those who cannot be vaccinated but want protection against the virus.
About a month after the FDA said Evusheld will wane in efficacy against new mutations, the agency warned that Eli Lilly’s COVID-19 drug bebtelovimab is unlikely to neutralize BQ.1 and BQ.1.1. Bebtelovimab is sold commercially for about $2,100 per vial.
It’s unlikely either drug will be pulled from the market if they both continue to offer some protection.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
